ong-term effects of ipragliflozin on nonalcoholic fatty liver disease in patients with type 2 diabetes

Not Applicable

• Conditions: Type 2 diabetes complicated by NAFLD

• Registration Number: JPRN-UMIN000040611
• Lead Sponsor: Ogawa Red Cross Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-06-01
• Study Completion: 2021-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who have history or current serious diabetic complication. 2. Patients that insulin dependence is suspected. 3. Patients who have history or current cardiac failure (New York Heart Association Class III or IV), myocardial infarction or cerebrovascular disorder. 4. Patients whose eGFR lower than 45 mL/min/1.73m2, serum creatinine higher than 1.5 mg/dL.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change from baseline in liver-to-spleen attenuation ratio (L/S ratio) by CT at 5 years

Secondary Outcome Measures

Name	Time	Method
Changes from baseline in AST, ALT, HbA1c, fasting plasma glucose, adiponectin, body weight, abdominal visceral adipose tissue, and subcutaneous adipose tissue at 5 years.